News

Press Releases

 
Press Releases
  Date Title and Summary View
May 10, 2016
Trial Conducted in Collaboration with the National Cancer Institute and AstraZeneca WALTHAM, Mass.--(BUSINESS WIRE)-- Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced that the first patient has bee...
May 2, 2016
Conference Call Today at 4:30 p.m. ET WALTHAM, Mass.--(BUSINESS WIRE)-- Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today provided an update on corporate activities during the quarter ended March 31, 20...
Apr 25, 2016
Dr. Krasner to Present Phase 1b Results of CRLX101 in Combination with Weekly Paclitaxel in Relapsed Ovarian Cancer WALTHAM, Mass.--(BUSINESS WIRE)-- Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced that Car...
Apr 25, 2016
WALTHAM, Mass.--(BUSINESS WIRE)-- Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced it will provide an update on corporate activities for the first quarter 2016 on May 2. Management will conduct a conference call a...
Apr 19, 2016
Late-Breaker Presents Results from Investigator-Sponsored Trial of CRLX101 in Combination with Avastin® (bevacizumab) in Patients with Platinum-Resistant Ovarian Cancer WALTHAM, Mass.--(BUSINESS WIRE)-- Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing ...
Apr 5, 2016
WALTHAM, Mass.--(BUSINESS WIRE)-- Cerulean Pharma Inc. (NASDAQ: CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced that Christopher D. T. Guiffre, President & Chief Executive Officer, will present at the 15th Annual Needham Healthcare Conference in New York on...
Mar 23, 2016
Phase 1 Data Published in Proceedings of the National Academy of Sciences (PNAS) WALTHAM, Mass.--(BUSINESS WIRE)-- Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced the publication of clinical data f...
Mar 21, 2016
Maximum Tolerated Dose Identified for Once-Every-Three-Weeks Regimen WALTHAM, Mass.--(BUSINESS WIRE)-- Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced the presentation of data from the Company's ongoing Pha...
Mar 16, 2016
One Late-Breaking Poster Reporting Interim Phase 2 CRLX101 Data in Ovarian Cancer Four Poster Presentations Featuring Preclinical and Clinical Data for CRLX101 and CRLX301 WALTHAM, Mass.--(BUSINESS WIRE)-- Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage...
Mar 10, 2016
Conference Call Today at 4:30 p.m. ET WALTHAM, Mass.--(BUSINESS WIRE)-- Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today provided an update on corporate activities during the quarter ended December 31, 2015. ...
Page: FirstPrevious
3
... NextLast
= add release to Briefcase
Shareholder Tools